Nicox, a renowned international ophthalmic R&D company, has announced the appointment of Gavin Spencer as its new Chief Executive Officer, effective February 2024. This strategic move marks a significant milestone in Nicox’s journey towards innovation and global expansion in the eyecare sector.
Gavin Spencer is a distinguished leader with a rich background in life sciences, boasting 25 years of experience and collaborations across America, Europe, and Asia. His career has been defined by a keen focus on strategy, operational excellence, and a vision for the big picture in the life sciences sector. From his early days in product development to his recent role as Executive Vice President, Spencer has consistently driven success through discovery, learning, leadership, and motivation.
Spencer’s professional journey is characterized by significant achievements and leadership roles at Nicox, where he has contributed for over 19 years. Prior to his appointment as CEO, he served as the Executive Vice President and Chief Business Officer, playing a pivotal role in corporate development, business development, investor relations, and corporate communications. His tenure at Nicox also includes key positions such as Executive Vice President of Corporate Development and Vice President of Business Development, during which he led numerous strategic transactions and partnerships that have shaped Nicox’s portfolio and market presence.
Nicox: Pioneering Ophthalmic Innovations
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.
The lead program of Nicox’s ophthalmic pipeline, NCX 470, is in Phase 3 clinical development targeting glaucoma. Our ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728, and a clinical-stage product candidate for dry eye disease licensed exclusively to a partner for the Chinese market, NCX 4251. We have two products which are commercialized in the U.S.; VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis, respectively, and which are being rolled-out in territories outside of the U.S. through partnerships.
